Use of repurposed and adjuvant drugs in hospital patients with covid-19: Multinational network cohort study

• Objective To investigate the use of repurposed and adjuvant drugs in patients admitted to hospital with covid-19 across three continents. Design Multinational network cohort study. Setting Hospital electronic health records from the United States, Spain, and China, and nationwide claims data from South Korea. Participants 303 264 patients admitted to hospital with covid-19 from January 2020 to December 2020. Main outcome measures Prescriptions or dispensations of any drug on or 30 days after the date of hospital admission for covid-19. Results Of the 303 264 patients included, 290 131 were from the US, 7599 from South Korea, 5230 from Spain, and 304 from China. 3455 drugs were identified. Common repurposed drugs were hydroxychloroquine (used in from <5 (<2%) patients in China to 2165 (85.1%) in Spain), azithromycin (from 15 (4.9%) in China to 1473 (57.9%) in Spain), combined lopinavir and ritonavir (from 156 (<2%) in the VA-OMOP US to 2,652 (34.9%) in South Korea and 1285 (50.5%) in Spain), and umifenovir (0% in the US, South Korea, and Spain and 238 (78.3%) in China). Use of adjunctive drugs varied greatly, with the five most used treatments being enoxaparin, fluoroquinolones, ceftriaxone, vitamin D, and corticosteroids. Hydroxychloroquine use increased rapidly from March to April 2020 but declined steeply in May to June and remained low for the rest of the year. The use of dexamethasone and corticosteroids increased steadily during 2020. Conclusions Multiple drugs were used in the first few months of the covid-19 pandemic, with substantial geographical and temporal variation. Hydroxychloroquine, azithromycin, lopinavir-ritonavir, and umifenovir (in China only) were the most prescribed repurposed drugs. Antithrombotics, antibiotics, H2 receptor antagonists, and corticosteroids were often used as adjunctive treatments. Research is needed on the comparative risk and benefit of these treatments in the management of covid-19. ©

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Public Health, Global Health, Social Medicine and Epidemiology (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Microbiology in the medical area (hsv//eng)

Nyckelord

azithromycin

ceftriaxone

corticosteroid

enoxaparin

hydroxychloroquine

lopinavir

lopinavir-ritonavir drug combination

quinolone derivative

ritonavir

vitamin D

adjuvant chemotherapy

administrative claims (health care)

adolescent

adult

aged

child

China

cohort analysis

diagnosis

drug combination

drug effect

drug repositioning

drug therapy

electronic health record

epidemiology

female

genetics

hospital patient

human

infant

male

middle aged

newborn

preschool child

procedures

safety

South Korea

Spain

treatment outcome

United States

very elderly

virology

young adult

Administrative Claims

Healthcare

Adrenal Cortex Hormones

Aged

80 and over

Chemotherapy

Adjuvant

Child

Preschool

Cohort Studies

COVID-19

Drug Combinations

Electronic Health Records

Fluoroquinolones

Humans

Infant

Newborn

Inpatients

Republic of Korea

SARS-CoV-2

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)